Viking Therapeutics, Inc.

Welcome to the Viking Therapeutics fourth quarter and full year 2022 financial results conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at that time, please press the star key followed by 1 on your touch-tone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference call is being recorded today, February 8th, 2023. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead.

Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 8th, 2023, will contain forward-looking statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and inversely and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made to date. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lamb for his initial comments.

Thanks, Stephanie, and good afternoon to everyone dialed in by phone or listening on the webcast. Today, we'll review our financial results for the fourth quarter and full year 2022 and provide an update on recent progress with our clinical programs and operations. 2022 was an exciting year for Viking as we expanded our development pipeline and advanced each of our three clinical programs. With respect to VK2809, our lead drug candidate for the treatment of NASH and fibrosis, we recently announced completion of enrollment in our Phase IIb voyage trial and we expect to announce top-line data from this study in the second quarter of 2023. In addition, the Phase I trial evaluating our newest program, the dual GLP-1 and GIP receptor agonist, VK2735, for the potential treatment of metabolic disorders, is continuing. We expect to report the initial data from this trial later this quarter. And finally, the Phase IB clinical trial evaluating VK0214 for the treatment of X-linked adrenal leukodystrophy also continues to enroll, and we expect to complete this study later this year. Our clinical advancements have significantly strengthened Viking's position as a leader in the development of novel, class-leading therapeutics for the treatment of metabolic disorders, and we look forward to reporting data from each of these three clinical programs this year. I'll provide further details on our operations and development activities after we review our fourth quarter and full year 2022 financial results. For that, I'll turn the call over to Greg Zanti, Vikings Chief Financial Officer.